Blood cancers—leukemia, lymphoma, and related conditions like chronic lymphocytic leukemia (CLL)—are diagnosed disproportionately in people over 65, placing them squarely in the Medicare population. Treatment has changed dramatically over the past decade: many patients now take an oral pill at home for years instead of sitting through infusion chemotherapy, while others receive one-time cell therapies that can cost hundreds of thousands of dollars. Each of these paths touches a different part of Medicare with very different cost-sharing. This guide maps the whole picture so you know what Medicare pays, where your out-of-pocket exposure is largest, and how supplemental coverage protects you from open-ended bills.

Diagnosis and Monitoring Under Part B

Getting to a precise blood-cancer diagnosis—and monitoring it over time—runs through Part B at 80 percent after the $257 deductible (2026), leaving you 20 percent coinsurance:

  • Blood counts (CBC), peripheral smear, and chemistry panels — billed as clinical laboratory tests, generally at no coinsurance
  • Bone marrow biopsy and aspiration — 20 percent coinsurance
  • Flow cytometry, cytogenetics (FISH), and molecular testing for markers such as BCR-ABL, IGHV mutation status, TP53/del(17p), and FLT3 — these guide drug choice and are covered as diagnostic lab work
  • CT, PET-CT, and MRI for staging lymphoma — 20 percent coinsurance
  • Lymph node biopsy — 20 percent coinsurance

Because many blood cancers are monitored for years (CLL in particular is often “watched and waited” before any treatment begins), these recurring Part B charges add up even before drug therapy starts.

The Core Cost Split: Oral Pills (Part D) vs. Infused Drugs (Part B)

The single most important financial fact in blood-cancer treatment is where your drug is administered, because that determines which part of Medicare pays and how much protection you have. This is the same Part B vs. Part D drug split that drives cost across nearly every serious diagnosis—but blood cancers show the divide at its most extreme.

Oral targeted therapy — Part D, capped at $2,000

A wave of oral targeted agents has transformed treatment of CLL, lymphoma, and some leukemias. Because you swallow them at home, they fall under Part D:

  • BTK inhibitors — ibrutinib (Imbruvica), acalabrutinib (Calquence), zanubrutinib (Brukinsa) for CLL and certain lymphomas
  • BCL-2 inhibitor — venetoclax (Venclexta)
  • FLT3 and IDH inhibitors — midostaurin (Rydapt), gilteritinib (Xospata), ivosidenib (Tibsovo) for acute myeloid leukemia
  • Tyrosine kinase inhibitors for CML — imatinib (now generic), dasatinib, nilotinib, bosutinib
  • PI3K and other oral agents for relapsed lymphoma

These drugs carry list prices of $10,000–$18,000 per month, but thanks to the 2025 Part D redesign, your total out-of-pocket for all covered Part D drugs is now capped at $2,000 per year. That cap is the difference between a manageable cost and financial catastrophe. You can also spread the $2,000 over the year using Medicare Prescription Payment Plan monthly installments. For a fuller walkthrough of tiers, the cap, and the payment plan, see our guide to Medicare Part D.

Infused chemotherapy and antibodies — Part B, no annual cap

Drugs given by IV or injection in a clinic or hospital outpatient department fall under Part B, where you owe 20 percent coinsurance with no annual limit:

  • Monoclonal antibodies — rituximab (Rituxan and biosimilars), obinutuzumab (Gazyva), and others, central to most lymphoma and CLL regimens
  • Infusion chemotherapy — bendamustine, cytarabine, anthracyclines, and combination regimens such as R-CHOP
  • Azacitidine/decitabine for myelodysplastic syndrome and AML (oral versions exist and shift to Part D)

A single rituximab infusion can run several thousand dollars, and a full lymphoma regimen of six or more cycles means 20 percent of a very large number, repeatedly, with no cap. This is where beneficiaries without supplemental coverage face the most danger.

The counterintuitive result

A patient on an expensive oral BTK inhibitor under Part D pays no more than $2,000 a year, while a patient on infused rituximab-based chemo under Part B can owe far more, because Part B coinsurance never stops accumulating. The route of administration—not the drug’s list price—often determines your bill. It’s always worth asking your oncologist whether an oral or infused option is clinically appropriate, and what each would cost you specifically.

CAR-T Cell Therapy: A Major Part B Exposure

Chimeric antigen receptor (CAR) T-cell therapy—products like Yescarta, Kymriah, Breyanzi, Tecartus, Abecma, and Carvykti—has become a standard option for relapsed large B-cell lymphoma, certain leukemias, and multiple myeloma. Medicare covers CAR-T for its approved indications.

The catch is cost. The cell product alone carries a list price around $400,000–$500,000, and the total episode—including hospitalization for the infusion and management of side effects like cytokine release syndrome—can exceed $1 million.

How you’re charged depends on the setting:

  • Inpatient CAR-T is paid under Part A, so your direct exposure is the Part A hospital deductible ($1,676 per benefit period in 2026) plus any daily coinsurance for a long stay—large, but bounded.
  • Outpatient CAR-T is paid under Part B at 20 percent coinsurance with no cap, which against a six- or seven-figure charge would be financially ruinous without supplemental coverage.

This single fact—that a Part B percentage applied to a million-dollar therapy has no ceiling—is the strongest possible argument for the supplemental protection described below.

Hospitalization, Transplant, and Supportive Care

  • Inpatient stays for induction chemotherapy (common in acute leukemia), complications, or stem cell/bone marrow transplant fall under Part A, subject to the benefit-period deductible and daily coinsurance.
  • Transplant itself is covered when medically necessary, including the inpatient stay and related Part B physician services.
  • Supportive drugs—anti-nausea medications, growth factors (G-CSF like filgrastim/pegfilgrastim), and transfusions—are typically billed under Part B when given in the clinic, or Part D when self-administered at home.
  • Hospice under Part A covers comfort-focused care for end-stage disease, including drugs for symptom relief, at little to no cost.

For a broader view of how all cancer care fits together across Parts A, B, and D, see our Medicare cancer treatment coverage guide.

Why Supplemental Coverage Is Decisive

Because blood-cancer treatment combines uncapped Part B coinsurance (infusions, antibodies, possibly CAR-T) with potentially years of therapy, the protection you choose at enrollment can mean a difference of tens of thousands of dollars.

  • Medigap Plan G pays your 20 percent Part B coinsurance with no annual limit, so even outpatient CAR-T or a long course of rituximab leaves you owing essentially only the small Part B deductible. See our comparison of Medigap plans.
  • Medicare Advantage caps your in-network out-of-pocket each year (commonly $4,000–$9,000), which protects you far better than Original Medicare alone—but it adds prior authorization and network restrictions that can complicate access to a specialized cancer center or a particular CAR-T facility. Weigh the trade-offs in our Medicare Advantage vs. Original Medicare comparison and the cost-focused breakdown.

The decision is hardest the day after a diagnosis, when guaranteed-issue Medigap rights may have lapsed and underwriting can block a switch. That’s why this choice is best made when you first enroll.

Help With Drug Costs

  • Extra Help (Low-Income Subsidy) dramatically lowers Part D costs—often to a few dollars per prescription—for those who qualify financially, which transforms the economics of oral targeted therapy.
  • Medicare Savings Programs can pay your Part B premium and, at the QMB level, your Part B coinsurance—directly relieving the uncapped infusion exposure. See our guide to Medicare Savings Programs.
  • Manufacturer and foundation assistance (Leukemia & Lymphoma Society, PAN Foundation, and drug-maker programs) can help with the $2,000 Part D cap, though rules on using them with Medicare vary.

The Bottom Line

Medicare covers the modern arsenal for leukemia and lymphoma—diagnostic testing, oral targeted pills, infused chemo and antibodies, CAR-T cell therapy, transplant, and hospice. But coverage is not the same as affordability. The $2,000 Part D cap has made expensive oral pills genuinely manageable, while uncapped Part B coinsurance on infusions and especially CAR-T remains the largest financial risk. Choosing the right supplemental coverage—ideally Medigap Plan G—and tapping Extra Help or Medicare Savings Programs where eligible is what turns world-class treatment into something you can actually afford. As with most serious diagnoses, planning your coverage before you need it is the single most valuable financial move, a theme that runs through all of our healthcare cost planning for retirement.